Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment, has released a Virtual Investor "What This Means" segment. In this presentation, Chief Medical Officer Dr. Robert Schwartz discusses the company's recent post hoc analysis of their proof-of-concept human clinical trial (PoC 1).
The analysis revealed significant outcomes including sustained pain reduction, improved quality of life, and 100% zero opioid use among trial participants. The company's focus remains on advancing innovative technologies in neurological disease management.
Autonomix Medical (NASDAQ: AMIX), azienda di dispositivi medici specializzata nella diagnosi e nel trattamento delle patologie del sistema nervoso, ha pubblicato una sezione virtuale per investitori intitolata "What This Means". In questa presentazione il Chief Medical Officer, Dr. Robert Schwartz, illustra l'analisi post hoc condotta sul loro trial clinico umano proof-of-concept (PoC 1).
Dall'analisi emergono risultati rilevanti, tra cui riduzione del dolore persistente, miglioramento della qualità della vita e uso di oppioidi pari a zero nel 100% dei partecipanti. L'azienda conferma l'impegno nello sviluppo di tecnologie innovative per la gestione delle malattie neurologiche.
Autonomix Medical (NASDAQ: AMIX), empresa de dispositivos médicos especializada en el diagnóstico y tratamiento de enfermedades del sistema nervioso, ha publicado un segmento virtual para inversores titulado "What This Means". En la presentación, el Chief Medical Officer, Dr. Robert Schwartz, explica el análisis post hoc de su ensayo clínico humano proof-of-concept (PoC 1).
El análisis mostró resultados significativos, incluyendo reducción sostenida del dolor, mejora de la calidad de vida y un 100% de ausencia de uso de opioides entre los participantes. La compañía mantiene su enfoque en avanzar tecnologías innovadoras para el manejo de enfermedades neurológicas.
Autonomix Medical (NASDAQ: AMIX)는 신경계 질환의 진단 및 치료를 전문으로 하는 의료기기 회사로, 가상 투자자용 'What This Means' 세그먼트를 공개했습니다. 이번 발표에서 수석의학책임자(Chief Medical Officer) Dr. Robert Schwartz는 개념증명 임상시험(PoC 1)에 대한 사후 분석 결과를 설명했습니다.
분석에서는 지속적인 통증 감소, 삶의 질 개선, 그리고 참가자 전원(100%)의 오피오이드 사용 제로와 같은 중요한 결과가 확인되었습니다. 회사는 신경계 질환 관리 분야의 혁신 기술 개발에 계속 주력하고 있습니다.
Autonomix Medical (NASDAQ: AMIX), société de dispositifs médicaux spécialisée dans le diagnostic et le traitement des maladies du système nerveux, a diffusé un segment virtuel pour investisseurs intitulé « What This Means ». Lors de cette présentation, le Chief Medical Officer, Dr. Robert Schwartz, revient sur l'analyse post hoc de leur essai clinique humain proof-of-concept (PoC 1).
L'analyse a mis en évidence des résultats significatifs, notamment une réduction durable de la douleur, une amélioration de la qualité de vie et une absence totale d'utilisation d'opioïdes chez 100% des participants. La société reste dédiée au développement de technologies innovantes pour la prise en charge des maladies neurologiques.
Autonomix Medical (NASDAQ: AMIX), ein Medizingeräteunternehmen, das auf Diagnose und Behandlung von Erkrankungen des Nervensystems spezialisiert ist, hat ein virtuelles Investorensegment "What This Means" veröffentlicht. In dieser Präsentation erläutert der Chief Medical Officer, Dr. Robert Schwartz, die nachträgliche Analyse ihres Proof-of-Concept-Humanstudienversuchs (PoC 1).
Die Analyse ergab bedeutende Ergebnisse, darunter
- Post hoc analysis showed sustained pain reduction in clinical trial participants
- Trial demonstrated 100% zero opioid use among participants
- Results showed quality of life improvements for patients
- None.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”)
THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a Virtual Investor “What This Means” segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and
The “What This Means” segment can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What were the key findings from Autonomix Medical's (NASDAQ: AMIX) PoC 1 clinical trial analysis?
Who presented Autonomix Medical's clinical trial results in the Virtual Investor segment?
What is Autonomix Medical's (AMIX) main business focus?
Where can investors access Autonomix Medical's Virtual Investor segment presentation?
